The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Evidence-based indications and safety profile

Pharmacology and Therapeutics

Volumn 102, Issue 3, 2004, Pages 177-193

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Autoimmune neuromuscular diseases; Chronic Inflammatory Demyelinating Polyneuropathy; CIPD; GBS; Guillain Barr syndrome; Intravenous immunoglobulin; Lambert Eaton myasthenic syndrome; LEMS; MG; Multifocal motor neuropathy; Myasthenia Gravis; SPS

Indexed keywords

ANALGESIC AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIAZEPAM; HEPARIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROPRANOLOL; STEROID;

AMYOTROPHIC LATERAL SCLEROSIS; ANAPHYLAXIS; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; CATARACT; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; DEMYELINATING NEUROPATHY; DERMATOMYOSITIS; DIABETES MELLITUS; DRUG INDICATION; DRUG SAFETY; EATON LAMBERT SYNDROME; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERVISCOSITY SYNDROME; HYPONATREMIA; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; KIDNEY TUBULE NECROSIS; LICHENOID ERUPTION; LUNG EMBOLISM; MIGRAINE; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NEUROMUSCULAR DISEASE; OBESITY; OSTEOPOROSIS; PETECHIA; PLASMAPHERESIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STIFF PERSON SYNDROME; STROKE; THROMBOEMBOLISM; THYMECTOMY; TREATMENT OUTCOME; URTICARIA; VASCULITIS;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CONTROLLED CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; NEUROMUSCULAR DISEASES; PRACTICE GUIDELINES;

EID: 3042856624     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2004.04.002     Document Type: Review

References (139)

1. Abe Y., Horiuchi A., Miyake M., Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev. 139:1994;5-19
2. Ahsan N. Intravenous immunoglobulin induced-nephropathy: a complication of IVIg therapy. J Nephrol. 11:1998;157-161
3. Ahsan N., Palmer B.F., Wheeler D., Greenlee R.G. Jr., Toto R.D. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med. 154:1994;1985-1987
4. Amemiya K., Semino-Mora C., Granger R.P., Dalakas M.C. Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol. 94:2000;99-104
5. Ankrust P., Muller F., Svenson M., Nordoy I., Bendtzen K., Froland S.S. Administration of intravenous immunoglobulin (IVIg) in vivo downregulatory effects on the IL-1 system. Clin Exp Immunol. 115:1999;136-143
6. Arakawa Y., Yoshimura M., Kobayashi S., Ichihashi K. The use of intravenous immunoglobulin in Miller-Fisher syndrome. Brain Dev. 15:1993;231-233
7. Azulay J.P., Blin O., Pouget J., Boucraut J., Bille-Turc F., Carles G., Serratrice G. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies. Neurology. 44:1994;429-432
8. Bain P.G., Motomura M., Newsom-Davis J., Misbah S.A., Chapel H.M., Lee M.L., Vincent A., Lang B. Effects of intravenous immunoglobulin (IVIg) treatment on muscle weakness and calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 47:1996;678-683
9. Basta M., Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 94:1994;1729-1735
10. Basta M., Kirshbom P., Frank M.M., Fries L.F. Mechanisms of therapeutic effect of high-dose intravenous immunoglobulin. J Clin Invest. 84:1989;1974-1981
11. Basta M., Illa I., Dalakas M.C. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain Barré syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol. 71:1996;227-229
12. Bayry J., Lacroix-Desmazes S., Carbonneil C., Misra N., Donkova V., Pashov A., Chevailler A., Mouthon L., Weill B., Bruneval P., Kazatchkine M.D., Kaveri S.V. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 101:2003;758-765
13. Bayry J., Lacroix-Desmazes S., Delignat S., Mouthon L., Weill B., Kazatchkine M.D., Kaveri S.V. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-α present in serum from patients with systemic lupus erythematosus. Arthritis Rheum. 48:2003;3497-3502
14. Bertorini T.E., Nance A.M., Horner L.H., Greene W., Gelfand M.S., Jaster J.H. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve. 19:1996;388-391
15. Björkander J., Hammarström L., Smith E., Buckley R.H., Cunningham-Rundles C., Hanson L.A. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol. 7:1987;8-15
16. Blasczyk R., Westhoff V., Grosse-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet. 341:1993;789-790
17. Bouche P., Moulonguet A., Ben Younes-Chennoufi A., Adams D., Baumann N., Meininger V., Leger J.M., Said G. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry. 59:1995;38-44
18. Brannagan T.H., Nagle K.J., Lange D.J., Rowland L.P. Complications of intravenous immune globulin treatment in neurologic disease. Neurology. 47:1996;674-677
19. Buchwald B., Ahangari R., Weishaupt A., Toyka K.V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol. 51:2002;673-680
20. Burks A.W., Sampson H.A., Buckley R.H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med. 314:1986;560-564
21. Castro L.H.M., Ropper A.H. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology. 43:1993;1034-1036
22. Chaudhry V., Corse A.M., Cornblath D.R., Kunel R.W., Drachman D.B., Freimer M.L., Griffin J.W. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol. 33:1993;237-242
23. Cherin P., Pelletier S., Teixeira A., Laforet P., Simon Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 58:2002;326
24. Comi G., Roveri L., Swan A., Willison H., Bojar M., Illa I., Karageorgiou C., Nobile-Orazio E., van den Nergh P., Swan T., Hughes R., Aubry J., Baumann N., Hadden R., Lunn M., Knapp M. Leger J.M., Bouche P., Mazanec R., Meucci N., van der Meche F., Toyka K. A randomized controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 249:2002;1370-1377
25. Constantinescu C.S., Chang A.P., McClusky L.F. Recurrent migraine and intravenous immune globulin therapy. N Engl J Med. 329:1993;583-584
26. Cook D., Dalakas M.C., Galdi A., Biondi D., Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology. 40:1990;212-214
27. Creange A., Gregson N.A., Hughes R.A. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FCgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol. 135:2003;91-95
28. Dalakas M.C. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 325:1991;1487-1498
29. Dalakas M.C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 44:1994;223-226
30. Dalakas M.C. Aseptic meningitis and intravenous immunoglobulin. Ann Intern Med. 122:1995;316-317
31. Dalakas M.C. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol. 37(S):1995;2-13
32. Dalakas M.C. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology. 48S:1997;64-69
33. Dalakas M.C. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med. 126:1997;721-730
34. Dalakas M.C. Meningitis and skin reactions after intravenous immunoglobulin therapy. Ann Intern Med. 127:1997;1130
35. Dalakas M.C. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis. Neurology. 51:1998;S37-S45. (Suppl)
36. Dalakas M.C. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the Treatment of autoimmune neurologic diseases. Neurology. 51:1998;S2-S8. (Suppl)
37. Dalakas M.C. Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr Opin Neurol. 12:1999;403-409
38. Dalakas M.C. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 22:1999;1479-1497
39. Dalakas M.C. Blockade of blocking antibodies in Guillain-Barré syndromes: "unblocking" the mystery of action of intravenous immunoglobulin. Ann Neurol. 51:2002;667-669
40. Dalakas M.C. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 59(Suppl 6):2002;S13-S21
41. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 291:2004;2367-2375
42. Dalakas M.C. Witnessing the introduction and use of IVIg in neurology. Dalakas M.C., Spath P.J. Intravenous Immunoglobulins in the Third Millennium. 2004;37-39 Parthenon, Lancaster, UK
43. Dalakas M.C., Clark W.M. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology. 60:2003;1736-1737
44. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 362:2003;971-982
45. Dalakas M.C., Illa I., Dambrosia J.M., Soueidan S.A., Stein D.P., Otero C., Dinsmore S.T., McCrosky S. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med. 329:1993;1993-2000
46. Dalakas M.C., Stein D.P., Otero C., Sekul E., Cupler E.J., McCrosky S. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol. 51:1994;861-864
47. Dalakas M.C., Quarles R.H., Farrer R.G., Dambrosia J., Soueidan S., Stein D.P., Cupler E.J., Sekul E.A., Otero C. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 40:1996;792-795
48. Dalakas M.C., Sonies B., Dambrosia J., Sekul E., Cupler E., Sivakumar K. Treatment of inclusion body, myositis with IVIg: a double-blind, placebo-control study. Neurology. 48:1997;712-716
49. Dalakas M.C., Fujii M., Li M., McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology. 55:2000;1531-1535
50. Dalakas M.C., Fujii M., Li M., Lutfi B., Kyhos J., McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 345:2001;1870-1876
51. Dalakas M.C., Koffman B., Fujii M., Spector S., Sivakumar K., Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 56:2001;323-327
52. Diegel M., Rankin B., Bolen J., Dubois P., Kiener P. Cross linking of Fc receptor to surface immunoglobulin on B cells provides on inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem. 269:1994;11409-11416
53. Dietrich G., Kazatchkine M.D. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains anti-idiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest. 85:1990;620-629
54. Drachman D.B. Myasthenia gravis. N Engl J Med. 330:1994;1797-1810
55. Dutch Guillain-Barré Syndrome Study Group Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol. 35:1994;749-752
56. Dwyer J.M. Manipulating the immune system with immune globulin. N Engl J Med. 326:1992;107-116
57. Dyck P.J., Litchy W.J., Kratz K.M., Suarez G.A., Low P.A., Pineda A.A., Windebank A.J., Karnes J.L., O'Brien P.C. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 36:1994;838-845
58. Ellie E., Combe C., Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med. 327:1992;1032-1033
59. Elliott J.L., Pestronk A. Progression of multifocal motor demyelinating neuropathy during apparently successful treatment with human immunoglobulin. Neurology. 44:1994;967-968
60. Farcas P., Avnun L., Frisher S., Herishanu Y.O., Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet. 350:1997;1747
61. Federico P., Zochodne D.W., Hahn A.F., Brown W.F., Feasby T.E. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology. 55:2000;1256-1262
62. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 22:1987;753-761
63. Gabriel C.M., Gregson N.A., Redford E.J., Davies M., Smith K.J., Hughes R.A.C. Human immunoglobulin ameliorates rat experimental allergic neuritis. Brain. 120:1997;1533-1540
64. Gajdos P. Intravenous immunoglobulin for myasthenia gravis. Dalakas M.C., Spath P.J. Intravenous Immunoglobulins in the Third Millennium. 2004;203-205 Parthenon, Lancaster, UK
65. Gajdos P.H., Chevret S., Clair B., Tranchant C., Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 41:1997;789-796
66. Gold R., Dalakas M.C., Toyka K.V. Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol. 2:2003;22-32
67. Guillain-Barré Study Group Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 35:1985;1096-1104
68. Hafer-Macko C., Hsieh S.T., Li C.Y., Ho T.W., Sheikh K., Cornblath D.R., McKhann G.M., Asbury A.K., Griffin J.W. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 40:1996;635-644
69. Hafer-Macko C.E., Sheikh K.A., Li C.Y., Ho T.W., Cornblath D.R., McKhann G.M., Asbury A.K., Griffin J.W. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 39:1996;625-635
70. Hague R.A., Eden D.B., Yap P.L., Mok J.Y.O., Rae P. Hyperviscosity in HIV infected children: a potential hazard during intravenous immunoglobulin therapy. Blut. 61:1990;66-67
71. Hahn A.F. Guillain-Barré syndrome. Lancet. 352:1998;635-641
72. Hahn A.F., Bolton C.F., Zochodne D., Feasby T.E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain. 119:1996;1067-1077
73. Hartung H.P., Pollard J.D., Harvey G.K., Toyka K.V. Immunopathogenesis and treatment of the Guillain-Barré syndrome - Part II. Muscle Nerve. 18:1995;154-164
74. Ho T.W., Hsieh S.T., Nachamkin I., Willison H.J., Sheikh K., Kiehlbauch J., Flanigan K., McArthur J.C., Cornblath D.R., McKhann G.M., Griffin J.W. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology. 48:1997;695-700
75. Ho T.W., Li C.Y., Cornblath D.R., Gao C.Y., Asbury A.K., Griffin J.W., McKhann G.M. Patterns of clinical recovery in Guillain Barré Syndrome. Neurology. 48:1997;695-700
76. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 7:2001;365-368
77. Howard J.F. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology. 51:1998;S30-S36. (Suppl)
78. Hughes R., Bensa S., Willison H., Van den Bergh P., Comi G., Illa I., Nobile-Orazio E., van Doorn P., Dalakas M.C., Bojar M. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 50:2001;195-201
79. Kanra G., Uzon A., Vajsar J., Castagna L., Secmeer G., Topaloglu H. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Pediatr Neurol. 1:1997;7-12
80. Kaveri S., Vassilev T., Hurex V., Lengagne R., Lefranc C., Cot S., Pouletty P., Glotz P., Kazatchkine M.D. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest. 97:1996;868-869
81. Kaveri S., Prasad N., Vassilev T., Hurez V., Pashov A., Lacroix-Desmazes S., Kazatchkine M. Modulation of autoimmune responses by intravenous immunoglobulin. Mult Scler. 3:1997;121-128
82. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 345:2001;747-755
83. Kazatchkine M.D., Dietrich G., Hurez V., Ronda N., Bellon B., Rossi F., Kaveri S.V. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin. Immunol Rev. 139:1994;79-107
84. Kekow J., Reinhold D., Pap T., Ansorge S. Intravenous immunoglobulins and transforming growth factor b. Lancet. 351:1998;184-185
85. Kieseier B.C., Dalakas M.C., Hartung H.P. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology. 59(Suppl 6):2002;S7-S12
86. Koffman B.M., Dalakas M.C. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve. 20:1997;1102-1107
87. Kornberg A.J. Clinical experience with intravenous immunoglobulin for treatment of pediatric Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Dalakas M.C., Spath P.J. Intravenous Immunoglobulin in the Third Millennium. 2004;181-185 Parthenon, Lancaster, UK
88. Kornberg A.J., Pestronk A., Bieser K., Ho T.W., McKhann G.M., Wu H.S., Jiang Z. The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol. 35:1994;234-237
89. Kurlander R.J., Hall J. Comparison of intravenous gammaglobulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest. 77:1986;2010-2018
90. Kuwabara S., Asahina M., Koga M., Mori M., Yuki N., Hattori T. Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody. Neurology. 51:1998;1656-1660
91. Leger J.M., Younes-Chennoufi A.B., Chassande B., Davila G., Bouche P., Baumann N., Brunet P. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 57S:1994;46-49
92. Malik U., Oleksowicz L., Latov N., Cardo L.J. Intravenous y-globulin inhibits binding of anti-GMI to its target antigen. Ann Neurol. 39:1996;136-139
93. Marchalonis J.J., Kaymaz H., Dedeoglu F., Schluter S.F., Yocum D.E., Edmundson A.B. Human autoantibodies reactive with synthetic autoantigens from T cell receptor Vβ chain. Proc Natl Acad Sci USA. 89:1992;3325-3329
94. Mastaglia F.L., Phillips B.A., Zilko P.J. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry. 65:1998;107-110
95. McCrone P., Chisholm D., Knapp M., Hughes R., Comi G., Dalakas M.C., Illa I., Kilindireas C., Nobile-Orazio E., Swan A., Van den Bergh L.H., Willison H.J. The INCAT Group Cost-utility analysis of intravenous immunoglobulin and polyradiculoneuropathies (CIDP). Eur J Neurol. 10:2003;687-694
96. Mendell J.R., Barohn R.J., Freimer M.L., Kissel J.T., King W., Nagaraja H.N., Rice R., Campbell W.W., Donofrio P.D., Jackson C.E., Lewis R.A., Shy M., Simpson D.M., Parry G.J., Rivner M.H., Thorton C.A., Bromberg M.B., Tandan R., Harati Y., Giuliani M.J. Working Group on Peripheral Neuropathy Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 56:2001;445-449
97. Nevo V., Pestronk A., Kornberg A.J., Connolly A.M., Yee W.C., Iqbal I., Shield L.K. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology. 47:1996;98-102
98. Newburger J.W., Takahashi M., Berser A.S., Burns J.C., Bastian J., Chung K.J., Colan S.D., Duffy C.E., Fulton D.R., Glode M.P., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 324:1991;1633-1639
99. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol. 115:2001;4-18
100. Nobile-Orazio E., Meucci N., Barbieri S., Carpo M., Scarlato G. High-dose immunoglobulin therapy in multifocal motor neuropathy. Neurology. 43:1993;537-544
101. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group Randomized trial of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in Guillain-Barré syndrome. Lancet. 349:1997;225-230
102. Raphael J.C., Chevret S., Harboun M., Jars-Guincestre M.C. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry. 71:2001;235-238
103. Rees J.H., Gregson N.A., Hughes R.A.C. Antiganglioside antibodies in Guillain Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol. 38:1995;809-816
104. Reisin R.C., Pociecha J., Rodriguez E., Massaro M.E., Arroyo H.A., Fejerman N. Severe Guillain-Barré syndrome in childhood treated with human immune globulin. Pediatr Neurol. 14:1996;308-312
105. Rigal D., Vermot-Desroches C., Heitz S., Bernaud J., Alfonsi F., Monier J.C. Effect of IVIg in peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effect on LFA-1 and CD56 molecules. Clin Immunol Immunopathol. 71:1994;309-314
106. Roifman C.M., Schroeder H., Berger M., Sorenson R., Ballow M., Buckley R.H., Gewurz A., Korenblat P., Sussman G., Lemm G. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol. 3(9):2003;1325-1333
107. Romano J.G., Rotta F.T., Potter P., Rosenfeld V., Santibanez R., Rocha B., Bradley W.G. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve. 21:1998;1327-1330
108. Roux K.H., Tankersley D.L. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol. 144:1990;1387-1392
109. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 291:2001;484-486
110. Saperstein D.S., Katz J.S., Amato A.A., Barohn R.J. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve. 24:2001;311-324
111. Schiff R.J. Transmission of viral infections through intravenous immune globulin. N Engl J Med. 331:1994;1649-1650
112. Sekul E.A., Cupler E.J., Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 121:1994;259-262
113. Sharma K.R., Cross J., Farronay O., Ayyar D.R., Shebert R.T., Bradley W.G. Demyelinating neuropathy in diabetes mellitus. Arch Neurol. 59:2002;758-765
114. Silbert P.L., Knezevic W.V., Bridge D.T. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology. 42:1992;257-258
115. Simmons Z., Wald J.J., Albers J.W. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve. 20:1997;1569-1575
116. Stangel M., Hartung H.-P., Marx P., Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci. 153:1998;203-214
117. Steg R.E., Lefkowitz D.M. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology. 44:1994;1180-1181
118. Svenson M., Hansen M.B., Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest. 92:1993;2533-2539
119. Takei S., Arora Y.K., Walker S.M. Intravenous immunoglobulin contains specific antibodies inhibitory of activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 91:1993;602-607
120. Tankersley D.L., Preston M.S., Finlayson J.S. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol. 25:1988;41-48
121. Terenghi F., Cappellari A., Bersano A., Carpo M., Barbieri S., Nobile-Orazio E. How long is IVIg effective in multifocal motor neuropathy? Neurology. 62:2004;666-668
122. Uher F., Dickler H.B. Cooperativity between B lymphocytes membrane molecules: independent ligand occupancy and crosslinking of antigen receptors and Fc gamma receptors downregulates B lymphocyte function. J Immunol. 137:1986;3124-3129
123. Van den Berg L.H., Kerkhoff H., Oey P.L., Franssen H., Mollee I., Vermeulen M., Jennekens F.G., Wokke J.H. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 59:1995;248-252
124. Van den Berg L.H., Franssen H., Wokke J.H.J. The long term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain. 121:1998;421-428
125. Van den Berg-Vos R.M., Franssen H., Wokke J.H., Van den Berg L.H. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain. 125:2002;1875-1886
126. van der Meche F.G.A., Schmitz P.I.M. the Dutch Guillain-Barré Study Group A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 326:1992;1123-1129
127. van Engelson B.G.M., Miller D.J., Pavelko K.D., Hommes O.R., Rodriguez M. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry (Suppl). 57:1994;65-68. (suppl)
128. van Koningsveld R., Schmitz P.I.M., van der Meché F.G., Visser L.H., Meulstee J., van Doorn P.A., Dutch G.B.S. Study Group Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomized trial. Lancet. 363:2004;92-96
129. Vassilev T., Gelin C., Kaveri S.V., Xilber M.T., Boumsell L., Kazatchkine M.D. Antibodies to the CD5 molecule in Normal Human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol. 92:1993;369-372
130. Vermeulen M., van Doorn P.A., Brand A., Strengers P.F.W., Jennekens F.G.I., Busch H.G.M. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 56:1993;36-39
131. Visser L.H., van der Meche F.G., Meulstee J., van Doorn P.A. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group. J Neurol Neurosurg Psychiatry. 64:1998;242-244
132. Voltz R.V., Rosen F., Yousry T., Beck J., Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a GBS patient treated with IV immunoglobulin. Neurology. 46:1996;250-251
133. Walter M.C., Lochmuller H., Toepfer M., Schlotter B., Reilich P., Schroder M., Muller-Felber W., Pongratz D. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 247:2000;22-28
134. Weiss M.D., Luciano C.A., Semino-Mora C., Dalakas M.C., Quarles R.H. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology. 51:1998;1738-1741
135. Weiss M.D., Dalakas M.C., Lauter C.J., Willison H.J., Quarles R.H. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J Neuroimmunol. 95:1999;174-184
136. Woodruff R.K., Griff A.P., Firkin F.L., Smith I.L. Fatal thrombic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet. 2:1986;217-218
137. Yu Z., Lennon V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 340:1999;227-228
138. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect Dis. 1:2001;29-37
139. Yuki N., Miyaga F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J Neurol Sci. 139:1996;160-162